FR2526016A1 - Procede de preparation des iodo-thyronines et en particulier de rt3 a partir de la thyroxine, par reduction electrochimique a potentiel controle - Google Patents
Procede de preparation des iodo-thyronines et en particulier de rt3 a partir de la thyroxine, par reduction electrochimique a potentiel controle Download PDFInfo
- Publication number
- FR2526016A1 FR2526016A1 FR8207590A FR8207590A FR2526016A1 FR 2526016 A1 FR2526016 A1 FR 2526016A1 FR 8207590 A FR8207590 A FR 8207590A FR 8207590 A FR8207590 A FR 8207590A FR 2526016 A1 FR2526016 A1 FR 2526016A1
- Authority
- FR
- France
- Prior art keywords
- iodo
- reduction
- thyroxine
- potential
- thyronine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims description 22
- 238000002360 preparation method Methods 0.000 title claims description 4
- 229910052740 iodine Inorganic materials 0.000 claims abstract description 15
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000011630 iodine Substances 0.000 claims abstract description 14
- 239000012736 aqueous medium Substances 0.000 claims abstract description 4
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical group IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 claims abstract description 3
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 claims description 20
- 229940034208 thyroxine Drugs 0.000 claims description 20
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 claims description 20
- 239000000047 product Substances 0.000 claims description 10
- WGTYBPLFGIVFAS-UHFFFAOYSA-M tetramethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)C WGTYBPLFGIVFAS-UHFFFAOYSA-M 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- 238000005868 electrolysis reaction Methods 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 239000002609 medium Substances 0.000 claims description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- OKIZCWYLBDKLSU-UHFFFAOYSA-M N,N,N-Trimethylmethanaminium chloride Chemical compound [Cl-].C[N+](C)(C)C OKIZCWYLBDKLSU-UHFFFAOYSA-M 0.000 claims description 3
- 239000011521 glass Substances 0.000 claims description 3
- ZLESINSMJVPWNE-AWEZNQCLSA-N (2s)-2-(diiodoamino)-3-[4-(4-hydroxyphenoxy)phenyl]propanoic acid Chemical class C1=CC(C[C@@H](C(=O)O)N(I)I)=CC=C1OC1=CC=C(O)C=C1 ZLESINSMJVPWNE-AWEZNQCLSA-N 0.000 claims description 2
- ZOMNIUBKTOKEHS-UHFFFAOYSA-L dimercury dichloride Chemical class Cl[Hg][Hg]Cl ZOMNIUBKTOKEHS-UHFFFAOYSA-L 0.000 claims description 2
- 239000008151 electrolyte solution Substances 0.000 claims description 2
- 238000005189 flocculation Methods 0.000 claims description 2
- 230000016615 flocculation Effects 0.000 claims description 2
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 claims description 2
- 229910052753 mercury Inorganic materials 0.000 claims description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 claims description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 claims description 2
- 229910052697 platinum Inorganic materials 0.000 claims description 2
- 239000002244 precipitate Substances 0.000 claims description 2
- 229940035722 triiodothyronine Drugs 0.000 claims description 2
- 238000004804 winding Methods 0.000 claims description 2
- 239000003792 electrolyte Substances 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims 2
- 241000357437 Mola Species 0.000 claims 1
- 238000005119 centrifugation Methods 0.000 claims 1
- 230000008030 elimination Effects 0.000 claims 1
- 238000003379 elimination reaction Methods 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- WGHUNMFFLAMBJD-UHFFFAOYSA-M tetraethylazanium;perchlorate Chemical compound [O-]Cl(=O)(=O)=O.CC[N+](CC)(CC)CC WGHUNMFFLAMBJD-UHFFFAOYSA-M 0.000 claims 1
- KKCIOUWDFWQUBT-AWEZNQCLSA-N L-thyronine Chemical compound C1=CC(C[C@H](N)C(O)=O)=CC=C1OC1=CC=C(O)C=C1 KKCIOUWDFWQUBT-AWEZNQCLSA-N 0.000 abstract description 8
- VSWSDTLXDWESGZ-AWEZNQCLSA-N (2s)-3-[4-(4-hydroxyphenoxy)phenyl]-2-(iodoamino)propanoic acid Chemical class C1=CC(C[C@@H](C(=O)O)NI)=CC=C1OC1=CC=C(O)C=C1 VSWSDTLXDWESGZ-AWEZNQCLSA-N 0.000 abstract description 7
- 239000002253 acid Substances 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 3
- 150000005622 tetraalkylammonium hydroxides Chemical class 0.000 abstract description 2
- ZHSOTLOTTDYIIK-ZDUSSCGKSA-N (2S)-2-amino-3-[4-(4-hydroxyphenoxy)-3,5-diiodophenyl]propanoic acid Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C=C1 ZHSOTLOTTDYIIK-ZDUSSCGKSA-N 0.000 abstract 1
- 150000007513 acids Chemical class 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000006722 reduction reaction Methods 0.000 description 20
- 150000001875 compounds Chemical class 0.000 description 10
- 235000013675 iodine Nutrition 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 244000309464 bull Species 0.000 description 6
- 239000012535 impurity Substances 0.000 description 5
- 238000003969 polarography Methods 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 238000003556 assay Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 210000001685 thyroid gland Anatomy 0.000 description 4
- NYPYHUZRZVSYKL-UHFFFAOYSA-N -3,5-Diiodotyrosine Natural products OC(=O)C(N)CC1=CC(I)=C(O)C(I)=C1 NYPYHUZRZVSYKL-UHFFFAOYSA-N 0.000 description 3
- NYPYHUZRZVSYKL-ZETCQYMHSA-N 3,5-diiodo-L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC(I)=C(O)C(I)=C1 NYPYHUZRZVSYKL-ZETCQYMHSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000005831 deiodination reaction Methods 0.000 description 3
- 229960000415 diiodotyrosine Drugs 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 125000001453 quaternary ammonium group Chemical group 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 210000004381 amniotic fluid Anatomy 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229940043671 antithyroid preparations Drugs 0.000 description 2
- 229960001955 benzylthiouracil Drugs 0.000 description 2
- PNXBXCRWXNESOV-UHFFFAOYSA-N benzylthiouracil Chemical compound N1C(=S)NC(=O)C=C1CC1=CC=CC=C1 PNXBXCRWXNESOV-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002989 hypothyroidism Effects 0.000 description 2
- 208000003532 hypothyroidism Diseases 0.000 description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000011946 reduction process Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- -1 tetramethyl hydroxide Chemical compound 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- XUIIKFGFIJCVMT-LBPRGKRZSA-N L-thyroxine Chemical compound IC1=CC(C[C@H]([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-LBPRGKRZSA-N 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 241000981595 Zoysia japonica Species 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- IYIKLHRQXLHMJQ-UHFFFAOYSA-N amiodarone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCCN(CC)CC)C(I)=C1 IYIKLHRQXLHMJQ-UHFFFAOYSA-N 0.000 description 1
- 229960005260 amiodarone Drugs 0.000 description 1
- 230000003208 anti-thyroid effect Effects 0.000 description 1
- 239000003200 antithyroid agent Substances 0.000 description 1
- JFIOVJDNOJYLKP-UHFFFAOYSA-N bithionol Chemical compound OC1=C(Cl)C=C(Cl)C=C1SC1=CC(Cl)=CC(Cl)=C1O JFIOVJDNOJYLKP-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000003749 cleanliness Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229950008325 levothyroxine Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000020845 low-calorie diet Nutrition 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000004452 microanalysis Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229960001866 silicon dioxide Drugs 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- ZCWKIFAQRXNZCH-UHFFFAOYSA-M tetramethylazanium;perchlorate Chemical compound C[N+](C)(C)C.[O-]Cl(=O)(=O)=O ZCWKIFAQRXNZCH-UHFFFAOYSA-M 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 208000005057 thyrotoxicosis Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
- C25B—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES FOR THE PRODUCTION OF COMPOUNDS OR NON-METALS; APPARATUS THEREFOR
- C25B3/00—Electrolytic production of organic compounds
- C25B3/20—Processes
- C25B3/25—Reduction
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
- C07C227/16—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions not involving the amino or carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/347—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups
- C07C51/377—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups by splitting-off hydrogen or functional groups; by hydrogenolysis of functional groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Electrochemistry (AREA)
- Materials Engineering (AREA)
- Metallurgy (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Electrolytic Production Of Non-Metals, Compounds, Apparatuses Therefor (AREA)
- Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8207590A FR2526016A1 (fr) | 1982-04-30 | 1982-04-30 | Procede de preparation des iodo-thyronines et en particulier de rt3 a partir de la thyroxine, par reduction electrochimique a potentiel controle |
| DE8383400830T DE3360383D1 (en) | 1982-04-30 | 1983-04-27 | Process for the preparation of iodo-thyronines and iodo-thyroacetic acids by electrochemical reduction at a controlled potential |
| EP83400830A EP0093653B1 (fr) | 1982-04-30 | 1983-04-27 | Procédé de préparation des iodo-thyronines et des acides iodothyroacétiques par réduction électrochimique à potentiel contrôlé |
| AT83400830T ATE14215T1 (de) | 1982-04-30 | 1983-04-27 | Verfahren zur herstellung von iodo-thyroninen und iodo-thyroessigsaeuren durch elektrochemische reduktion bei kontrolliertem potential. |
| US06/489,536 US4490221A (en) | 1982-04-30 | 1983-04-28 | Process for preparing iodothyronines and iodothyroacetic acids by electrochemical reduction at controlled potential |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8207590A FR2526016A1 (fr) | 1982-04-30 | 1982-04-30 | Procede de preparation des iodo-thyronines et en particulier de rt3 a partir de la thyroxine, par reduction electrochimique a potentiel controle |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2526016A1 true FR2526016A1 (fr) | 1983-11-04 |
| FR2526016B1 FR2526016B1 (enExample) | 1984-07-27 |
Family
ID=9273626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR8207590A Granted FR2526016A1 (fr) | 1982-04-30 | 1982-04-30 | Procede de preparation des iodo-thyronines et en particulier de rt3 a partir de la thyroxine, par reduction electrochimique a potentiel controle |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US4490221A (enExample) |
| EP (1) | EP0093653B1 (enExample) |
| AT (1) | ATE14215T1 (enExample) |
| DE (1) | DE3360383D1 (enExample) |
| FR (1) | FR2526016A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6716452B1 (en) | 2000-08-22 | 2004-04-06 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| US6740680B1 (en) * | 1999-04-26 | 2004-05-25 | Becton Pharma, Inc. | Pharmaceutical compositions to tetrac and methods of use thereof |
| US6627660B1 (en) | 1999-11-16 | 2003-09-30 | New River Pharmaceuticals Inc. | Stabilized thyroxine compounds |
| US8394813B2 (en) | 2000-11-14 | 2013-03-12 | Shire Llc | Active agent delivery systems and methods for protecting and administering active agents |
| US7169752B2 (en) | 2003-09-30 | 2007-01-30 | New River Pharmaceuticals Inc. | Compounds and compositions for prevention of overdose of oxycodone |
| US20060014697A1 (en) | 2001-08-22 | 2006-01-19 | Travis Mickle | Pharmaceutical compositions for prevention of overdose or abuse |
| US7919533B2 (en) * | 2004-10-20 | 2011-04-05 | Sal Abraham | Diiodothyroacetic acid and method of use |
| US20100047662A1 (en) * | 2008-08-22 | 2010-02-25 | Ford Global Technologies, Llc | Catalyst Layers Having Thin Film Mesh Catalyst (TFMC) Supported on a Mesh Substrate and Methods of Making the Same |
| US20110143263A1 (en) * | 2010-04-29 | 2011-06-16 | Ford Global Technologies, Llc | Catalyst Layer Having Thin Film Nanowire Catalyst and Electrode Assembly Employing the Same |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2894977A (en) * | 1955-12-24 | 1959-07-14 | Hoechst Ag | Process of preparing phenoxycinnamic acid derivatives |
| US3477954A (en) * | 1966-06-29 | 1969-11-11 | Armour Pharma | Phosphonium iodide complexes of thyroxine,methods of preparing same,and methods of preparing 3,5,3'-l-triiodothyronine therefrom |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1072998B (de) * | 1957-08-21 | 1960-01-14 | Farbwerke Hoechst Aktiengesellschaft vormals Meister Lucius &. Brüning, Frankfurt/M | Verfahren zur Herstellung von substituierten Diphenyläthern |
| US3677916A (en) * | 1971-03-11 | 1972-07-18 | Dow Chemical Co | Electrolytic reduction of 1,2,3,4-tetrachlorobenzene to obtain 1,2,4-trichlorobenzene |
-
1982
- 1982-04-30 FR FR8207590A patent/FR2526016A1/fr active Granted
-
1983
- 1983-04-27 EP EP83400830A patent/EP0093653B1/fr not_active Expired
- 1983-04-27 DE DE8383400830T patent/DE3360383D1/de not_active Expired
- 1983-04-27 AT AT83400830T patent/ATE14215T1/de not_active IP Right Cessation
- 1983-04-28 US US06/489,536 patent/US4490221A/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2894977A (en) * | 1955-12-24 | 1959-07-14 | Hoechst Ag | Process of preparing phenoxycinnamic acid derivatives |
| US3477954A (en) * | 1966-06-29 | 1969-11-11 | Armour Pharma | Phosphonium iodide complexes of thyroxine,methods of preparing same,and methods of preparing 3,5,3'-l-triiodothyronine therefrom |
Also Published As
| Publication number | Publication date |
|---|---|
| US4490221A (en) | 1984-12-25 |
| FR2526016B1 (enExample) | 1984-07-27 |
| ATE14215T1 (de) | 1985-07-15 |
| EP0093653B1 (fr) | 1985-07-10 |
| EP0093653A1 (fr) | 1983-11-09 |
| DE3360383D1 (en) | 1985-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2191772C2 (ru) | ПРОИЗВОДНЫЕ ПРОСТОГО ДИАЛКИЛОВОГО ЭФИРА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ПРОЯВЛЯЮЩАЯ АКТИВНОСТЬ В ОТНОШЕНИИ СНИЖЕНИЯ В ПЛАЗМЕ УРОВНЯ ЛИПОПРОТЕИНА (a), АПОЛИПОПРОТЕИНА В, ТРИГЛИЦЕРИДОВ, КОМПЛЕКСА ХОЛЕСТЕРИНА С ЛИПОПРОТЕИНАМИ НИЗКОЙ ИЛИ ОЧЕНЬ НИЗКОЙ ПЛОТНОСТИ И В ОТНОШЕНИИ ПОВЫШЕНИЯ В ПЛАЗМЕ УРОВНЯ АПОЛИПОПРОТЕИНА А-I ИЛИ Е, КОМПЛЕКСА ХОЛЕСТЕРИНА С ЛИПОПРОТЕИНАМИ ВЫСОКОЙ ПЛОТНОСТИ, СПОСОБ СНИЖЕНИЯ В ПЛАЗМЕ УРОВНЯ ЛИПОПРОТЕИНА (a), АПОЛИПОПРОТЕИНА В, ТРИГЛЕЦИРИДОВ, КОМПЛЕКСА ХОЛЕСТЕРИНА С ЛИПОПРОТЕИНАМИ НИЗКОЙ ИЛИ ОЧЕНЬ НИЗКОЙ ПЛОТНОСТИ, СПОСОБ ПРОФИЛАКТИКИ ИЛИ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ СОСУДОВ, СВЯЗАННЫХ СО СНИЖЕНИЕМ В ПЛАЗМЕ УРОВНЯ ЛИПОПРОТЕИНА (a), АПОЛИПОПРОТЕИНА В, ТРИГЛЕЦИРИДОВ, КОМПЛЕКСА ХОЛЕСТЕРИНА С ЛИПОПРОТЕИНАМИ НИЗКОЙ ИЛИ ОЧЕНЬ НИЗКОЙ ПЛОТНОСТИ, А ТАКЖЕ С ПОВЫШЕНИЕМ В ПЛАЗМЕ УРОВНЯ КОМПЛЕКСА ХОЛЕСТЕРИНА С ЛИПОПРОТЕИНАМИ ВЫСОКОЙ ПЛОТНОСТИ ИЛИ АПОЛИПОПРОТЕИНА А-I ИЛИ Е, ИЛИ ИНСУЛИННЕЗАВИСИМОГО САХАРНОГО ДИАБЕТА, СПОСОБ ПОВЫШЕНИЯ В ПЛАЗМЕ УРОВНЯ КОМПЛЕКСА ХОЛЕСТЕРИНА С ЛИПОПРОТЕИНАМИ ВЫСОКОЙ ПЛОТНОСТИ ИЛИ АПОЛИПОПРОТЕИНА A-I ИЛИ E | |
| Wada et al. | A simple method for the quantitative analysis of urinary delta-aminol evulinic acid to evaluate lead absorption | |
| Wirz-Justice et al. | Diurnal and seasonal variations in human platelet serotonin in man | |
| FR2526016A1 (fr) | Procede de preparation des iodo-thyronines et en particulier de rt3 a partir de la thyroxine, par reduction electrochimique a potentiel controle | |
| MacKinnon et al. | Modulation by the thyroid state of intracellular calcium and contractility in ferret ventricular muscle. | |
| US20090017549A1 (en) | Apparatus and Method for Determining The Concentration of Iodine-Containing Organic Compounds in an Aqueous Solution | |
| Eriksson et al. | Islet amyloid polypeptide plasma concentrations in individuals at increased risk of developing type 2 (non-insulin-dependent) diabetes mellitus | |
| Gallagher et al. | The relationship of the anticonvulsant properties of primidone to phenobarbital | |
| Vais et al. | An anodized nanostructure of Ni/Cu alloy synthesized in ethaline for electrocatalytic oxidation and amperometric determination of l-carnitine | |
| Nangaku et al. | Pathogenesis and management of dialysis-related amyloid bone disease | |
| Agrup et al. | 5-S-cysteinyldopa in the urine of melanoma patients | |
| Jaber et al. | Pharmacokinetics and pharmacodynamics of glyburide in young and elderly patients with non-insulin-dependent diabetes mellitus | |
| Laurberg et al. | Radioimmunological determination of reverse triiodothyronine in unextracted serum and serum dialysates | |
| Ghadimi et al. | Salient features of histidinemia | |
| FR2656424A1 (fr) | Procede d'electro-analyse rapide des liquides biologiques, dispositif utilise a cet effet et applications dans le domaine biologique. | |
| FR2468648A1 (fr) | Procede pour mesurer la difference de potentiel entre electrodes afin de determiner la croissance de bacteries | |
| Delmas-Beauvieux et al. | 13C nuclear magnetic resonance study of glycogen resynthesis in muscle after glycogen-depleting exercise in healthy men receiving an infusion of lipid emulsion. | |
| Praticò | Oxidative imbalance and lipid peroxidation in Alzheimer's disease | |
| CN114957293B (zh) | 用于特异性识别胰岛素的基于鸟嘌呤的花菁探针及其制备方法 | |
| JPH095321A (ja) | 生化学物質測定装置及びそれに適用する唾液収集方法 | |
| LU85296A1 (fr) | Procede de preparation de derives de pyrimidinetrione | |
| SU1390567A1 (ru) | Способ диагностики псориаза | |
| SU1746313A1 (ru) | Способ диагностики воспалительного процесса при мочекаменной болезни | |
| SU1397812A1 (ru) | Способ количественного определени метионина | |
| JP4503228B2 (ja) | キノリンオキシド誘導体およびその製造方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GC | Lien (pledge) constituted | ||
| ST | Notification of lapse |